N/A
Completed N=223
Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee
Osteoarthritis of Knee
Source: ClinicalTrials.gov NCT00790985 ↗
Enrolled (actual)
223
Serious AEs
0.0%
Results posted
Nov 2022
Primary outcomePrimary: Western Ontario and McMaster Universities Arthritis (WOMAC) Composite Score: Percent Change From Baseline to Week 12. — 85.75; 69.97 percentage of change
Summary
To compare flavocoxid with naproxen for patients with moderate to severe osteoarthritis of the knee.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Western Ontario and McMaster Universities Arthritis (WOMAC) Composite Score: Percent Change From Baseline to Week 12. |
85.75; 69.97 | — |
Eligibility Criteria
Inclusion Criteria
- Willing and able to read and understand informed consent and questionnaires in English.
- Adults of either gender age 35-75 years, in general good health.
- Established X-ray diagnosis of osteoarthritis of at least one knee.
- Taken NSAID including COX-2 (cyclo-oxygenase-2) inhibitor in full therapeutic dose for at least one month prior to screening.
- Able and will to discontinue osteoarthritis medications until flare criteria met.
- BMI 2.0 or nephrotic syndrome with 24 hour protein excretion >1000mg.
- Intra-articular injection of any hyaluronic acid preparation in the target knee joint within 4 months of baseline visit.
- Intra-articular injection of a corticosteroid in the target knee joint within 2 months of the baseline visit.
- BMI>45
- History of allergic reaction to flavonoid or flavan containing foods or products (example: red wine, colored fruits and vegetable, brazil nuts, tea, natto)
- History of allergy to aspirin, naproxen or other NSAID
- History of substance abuse including alcohol, or any psychiatric condition that may impair the subject's ability to comply with the study requirements.
- Any medical condition that, in the opinion of the investigator, might put the subject at undue risk or might interfere with the subject's ability to participate in the study.
- Participation in another clinical trial within 30 days or 7 half lives of the study agent, whichever is longer, of the screening visit.
Data sourced from ClinicalTrials.gov (NCT00790985). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.